Sequencing of Biologic and Target Synthetic Disease-Modifying Anti-Rheumatic Drugs in Psoriatic Arthritis: Are we Ready to Redefine the Treatment Strategy? A Perspective by Ennio Lubrano, Silvia Scriffignano, Fabio Massimo Perrotta

Subjects: Get full text

The impact of EMA recommendations on the real-life use of Janus kinases inhibitors for rheumatoid arthritis: the Expanded Risk Score in RA as a tool to quantify the risk of cardiov... by Ennio Giulio Favalli, Ennio Giulio Favalli, Gilberto Cincinelli, Gilberto Cincinelli, Sabino Germinario, Sabino Germinario, Raffaele Di Taranto, Raffaele Di Taranto, Francesco Orsini, Francesco Orsini, Gabriella Maioli, Gabriella Maioli, Martina Biggioggero, Matteo Ferrito, Matteo Ferrito, Roberto Caporali, Roberto Caporali

Subjects: Get full text

Difficult-to-treat psoriatic arthritis: refining the definition using a statistical model in a real-life cohort by Ennio Giulio Favalli, Ennio Giulio Favalli, Giacomo Biganzoli, Gilberto Cincinelli, Gilberto Cincinelli, Matteo Ferrito, Matteo Ferrito, Ester Luconi, Maria Manara, Martina Biggioggero, Patrizia Boracchi, Patrizia Boracchi, Roberto Caporali, Roberto Caporali

Subjects: Get full text

Truth unveiled by time and the marbled definition of D2T-RA: retrospective analysis on the persistence of the difficult-to-treat status among refractory RA patients by Gilberto Cincinelli, Gabriella Maioli, Cristina Posio, Ennio Giulio Favalli, Francesca Ingegnoli, Roberto Caporali

Subjects: Get full text